/C O R R E C T I O N -- Piramal Pharma Solutions/
In the news release, Piramal Pharma Solutions Launches New Microbiology Laboratory at Its Lexington, KY Sterile Injectable Facility, issued 06-Oct-2026 by Piramal Pharma Solutions over PR Newswire, we are advised by the company that changes have been made to the caption accompanying the first ima...
Piramal Pharma Solutions Advances Sustainability Efforts with Solar Power Plant Addition at Morpeth, UK Site
* Piramal Pharma Solutions is installing a ground-mounted solar power plant (4.3 MWp) at its integrated drug substance and drug product site in Morpeth, UK. * The new plant will provide renewable energy directly to the site through a behind-the-meter setup, supporting Piramal's commitment to re...
Piramal Pharma Solutions Highlights Strong Performance Across More Than 200 Customer Audits
* Piramal Pharma Solutions completed more than 200 customer audits and received over 70 approvals from regulatory agencies across its global network over the past year, with strong overall outcomes. * This milestone reflects the Company's long-range quality strategy focused on sustained compl...
Piramal Pharma Solutions Announces Partnership with Botanix to Support Drug Substance Development
* Piramal Pharma Solutions has entered into an agreement with Botanix SB Inc., a subsidiary of Botanix Pharmaceuticals Limited, to support the development and commercial supply of Sofdra®. * Sofdra is the first and only FDA-approved new chemical entity (NCE) for the treatment of primary axill...
Piramal Pharma Solutions Unveils State-of-the-Art Payload-Linker Suite at its Riverview, Michigan Facility
* The Riverview facility provides comprehensive services for active pharmaceutical ingredients (APIs) and high potency APIs (HPAPIs), including specialized solutions for payload-linkers. * This cutting-edge suite will significantly enhance the company's ability to support global payload-linke...
Piramal Pharma Limited Announces Results for Q4 and Full-year FY26
MUMBAI, India, April 28, 2026 /PRNewswire/ -- Piramal Pharma Limited (NSE: PPLPHARMA | BSE: 543635), a leading global pharmaceutical, health and wellness company, today announced its standalone and consolidated results for the Fourth Quarter (Q4) and Full-year ended 31st March 2026. Consolidated...
